All
6 Jun 2026
The Great Technology Plan for Wellness, to simplify only slightly, envisions a path to health that runs through data: collect more (through wearables and blood tests), analyze with AI, and deliver personalized coaching that improves as the data grow and the models sharpen. It sounds sensible, and one day it may even deliver — I’m long-term optimistic. But today it...
3 Jun 2026
In wet labs and dry labs, investor meetings, and medical conferences, it’s impossible to avoid discussions about how AI is transforming the way medicines are discovered. It is and it isn’t. This “AI in drug discovery” dogma gets something wrong. It assumes that “AI in drug discovery” is one thing. It is not. It’s true that AI systems help drug...
2 Jun 2026
Becky Pferdehirt is today’s guest on The Long Run. Becky is the CEO of Radial, the Emeryville, CA-based life sciences division of the Astera Institute. The nonprofit made news in March when it committed $500 million to Radial with a mission to reimagine data generation, sharing, infrastructure and tools necessary to create the best conditions for AI to help solve...
24 May 2026
Back by popular demand – my highly curated list of summer content recommendations for TR readers. Books Inside the Box – David Epstein By now, you’ve read, or should have read Range, David Epstein’s previous book and his paean to generalists (my reflections here). Now, he introduces us to an intriguing paradox – the unexpected power of constraints to inspire...
19 May 2026
Jeremy Levin is today’s guest on The Long Run. He is the executive chairman and founder of New York-based Ovid Therapeutics. He’s also a board member of the Biotechnology Innovation Organization, and a past chairman of the BIO board of directors. Jeremy has a new book out today, called “Biotech in the Balance: Saving a Strategic Industry in an Age...
16 May 2026
This week’s Duke-Margolis Health Policy Conference (video here) left me feeling there’s a remarkable opportunity to leverage technology to dramatically improve healthcare — and there’s almost no chance of it happening within the current healthcare system. A number of speakers (including UCSF’s Bob Wachter, my WSJ review of his recent book here) were genuinely enthusiastic about the transformative possibility of...
5 May 2026
Richard Pops is the latest guest on The Long Run. Richard is the chairman and CEO of Alkermes. He’s one of the longest-serving biotech leaders ever, with a 35-year career at the helm of a single company. Rich is also one of the more issue-oriented and politically engaged industry leaders. As the head of a mid-sized biopharma company, he has...